Cover Image
市場調查報告書

靜脈注射免疫球蛋白 (IVIg) 的全球市場

Intravenous Immunoglobulin (IVIg)

出版商 Global Industry Analysts, Inc. 商品編碼 252361
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
靜脈注射免疫球蛋白 (IVIg) 的全球市場 Intravenous Immunoglobulin (IVIg)
出版日期: 2017年08月01日 內容資訊: 英文 187 Pages
簡介

本報告提供全球靜脈注射免疫球蛋白(IVIg)市場相關調查、各地區趨勢、2013年∼2020年的預測、市場參與企業簡介等彙整資料。

第1章 簡介、調查方法、產品定義

第2章 摘要整理

  • 產業概要
    • 靜脈注射免疫球蛋白
    • FDA已經過核准及非標籤藥物的靜脈注射免疫球蛋白治療方法清單
    • 各地區市場
    • 推動成長要素和市場課題
    • 競爭模式
    • 全球大企業所提供的IVIg產品
  • 市場趨勢
  • 血漿蛋白質:概要
  • 治療概要
    • 免疫球蛋白概要
    • IVIg和SCIg
    • 產品及治療的成本
    • 副作用
    • 治療頻率
    • 安全性
    • 患者對治療的反應
    • 治療部位
    • IVIg治療的簡介
    • 血管內免疫球蛋白
    • IVIg作用機制 其他
  • 法律上的認證
  • 產品創新/引進
  • 近幾年的產業活動
  • 全球參與企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
  • 亞太地區
    • 澳洲
    • 中國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7776

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -

Bharat Serums and Vaccines Limited
Biotest AG
China Biologic Products, Inc.
CSL Limited
Grifols, S.A.
Hualan Biological Engineering Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Immunoglobulins to See Steady Growth
    • Table 1: Global Immunoglobulins Market by Segment (2017 & 2022): Percentage Breakdown of Market Value for Intravenous IG, Hyperimmunes and Subcutaneous IG (includes corresponding Graph/Chart)
    • Table 2: World Market for Immunoglobulins by Indication (2016): Percentage Breakdown of Market Value for CIDP, PI, Off-Label and Others (includes corresponding Graph/Chart)
    • Table 3: Leading Players in the Global Immunoglobulin Market (2016E): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart)
  • Intravenous Immunoglobulin - A Proliferating Biologic
  • Application Areas - A Brief Review
  • Market Outlook
    • Growth Drivers and Market Challenges
  • Competitive Scenario
    • Table 4: Leading Players in the Global IVIg Market (2017E): Percentage Breakdown of Revenues for CSL, Grifols, Shire and Others (includes corresponding Graph/Chart)
    • Grifols Continues to Consolidate Market Position
      • Comparison of Select Drugs and Approved Indications
    • CSL Sees Robust Growth in Immunoglobulin Franchise
    • Shire Continues to Invest Big in Immunoglobulins
    • Bivigam Changes Hands Consequent to Unexpected Turn of Events

2. MARKET TRENDS

  • Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
  • Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
  • IVIg - The Mainstay of PI Therapy
  • Subcutaneous IG Formulations Gain Therapeutic Foothold
    • Table 5: Global Subcutaneous Immunoglobulin Market: 2016-2024 (includes corresponding Graph/Chart)
  • Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
  • Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market
  • Synthetic Replacements to IVIg Therapy
  • IVIg Therapy - Home-based vs. Outpatient Settings
  • Per Capita Consumption Rate Varies Across Countries
    • Table 6: Global Intravenous Immunoglobulin Market (2016): Per Capita Consumption for Select Countries (in Kilograms per Million Inhabitants) (includes corresponding Graph/Chart)
  • Favorable Reimbursement and High Usage make US the Largest Consumer
  • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
  • Aging Global Population: Major Opportunity Indicator
    • Table 7: Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart)
    • Table 8: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)
    • Table 9: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Foster Growth
    • Table 10: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)

3. PLASMA PROTEINS - AN OVERVIEW

  • Plasma and Plasma Derivatives Continue to Dominate Blood Components Market
    • Table 11: World Plasma Products Market by Geographic Region (2016): Percentage Breakdown of Market Value for Asia-Pacific, Europe, North America and Rest of World (includes corresponding Graph/Chart)
    • Table 12: World Plasma Products Market by Protein (2016): Percentage Breakdown of Market Value for Albumin, All Factors, IVIG and Others (includes corresponding Graph/Chart)
    • Table 13: Leading Players in the Global Plasma Market (2016): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart)
    • Table 14: Leading Players in Plasma Fractionation by Capacity (2017 & 2022): Percentage Breakdown of Annual Capacity for CSL, Grifols, Kedrion, Octapharma, Shire and Others (includes corresponding Graph/Chart)
  • Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW

  • Immunoglobulins Overview
  • IVIg and SCIg: A Face-off!
  • Cost of Product and Treatment
  • Side-Effects
  • Frequency of Treatment
  • Safety Considerations
  • Patient Response to Treatment Varies
  • Site of Care
  • IVIg Therapy Introduction
  • Intravenous Immunoglobulin
  • Mechanism of IVIg Action
  • IVIg Dosage and Treatment Response Time
  • Common IVIg Intravenous Dosing Recommendations by Indication
  • Complications and Side Effects of Using IVIg
  • Precautions to be Undertaken
  • Intravenous Immunoglobulin - Indications
  • FDA Approved Indications for IVIg
  • Off-Label Usage of IVIg
    • Select Off-Label Indications for IVIg
  • Applications by Medical Specialty
  • Neurology
  • Hematology
  • Immunology
  • Dermatology
  • Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. RECENT INDUSTRY ACTIVITY

  • LFB Group's 10% IVIg Gains More Approvals in Europe
  • CSL Acquires Majority Stake in Ruide
  • Baxter Acquires Claris Injectables
  • ADMA Biologics Takes Over BTBU
  • Green Cross Receives FDA Complete Response Letter for IVIG-SN
  • China Biologic Products Completes Acquisition of Guizhou Taibang
  • ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial
  • Kroger Combines Axium Pharmacy and Modern HC
  • Shire Acquires Baxalta
  • FDA Accepts BLA for IVIG-SN from Green Cross
  • Kedrion Bags US Commercial Rights to BIVIGAM(r)
  • China Biologic Products to Commence Clinical Trials on Next-Gen IVIG Products
  • FDA Clears ProMetic's IND for IVIg
  • LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe
  • Baxter Divests its BioScience Division
  • Emergent BioSolutions Acquires Cangene
  • CMS Begins Evaluation of Payment for In-home IVIG Administration

6. FOCUS ON SELECT PLAYERS

  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc. (China)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Shire plc (Ireland)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

7. GLOBAL MARKET PERSPECTIVE

  • Value Analytics
    • Table 15: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 16: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 17: World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
  • Volume Analytics
    • Table 18: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 19: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 20: World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Volume Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Favorable Reimbursement and High Usage Drive Market
      • Approved and Marketed Human Immunoglobulin Products in the US
    • Tough Times Ahead for IVIG
    • ProMetic's IVIg - A Prospective New Drug in the Crowded Market
    • Ageing Demographics: A Key Market Driver
    • Table 21: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Intravenous Immunoglobulin Reimbursement Scenario
    • Higher Plasma Center Numbers Key to Secure Raw Material Supply, Costs Remain A Bottleneck
    • Table 22: Number of Plasma Centers in Operation in the US for Leading Players
    • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
      • US Blood Supply System - A Schematic
    • Strategic Corporate Developments
  • B. Market Analytics
    • Value Analytics
    • Table 23: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 24: The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 25: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 26: The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • ProMetic - Striving towards Plasma Self Sufficiency
    • Strategic Corporate Development
  • B. Market Analytics
    • Value Analytics
    • Table 27: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 28: Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 29: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 30: Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Value Analytics
    • Table 31: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 32: Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 33: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 34: Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Table 35: European Immunoglobulin (IVIg and SCIg) Consumption (2016): Per Capita Consumption in Kilograms per Million Inhabitants for Select Leading Countries (includes corresponding Graph/Chart)
    • Ageing Population Drives Demand
    • Table 36: Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart)
    • Table 37: Life Expectancy at Birth for Select Countries in Europe: 2016 (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Value Analytics
    • Table 38: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 39: European Historic Review for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 40: European 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 41: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 42: European Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Research Initiative in France
      • High-dose Intravenous Immunoglobulin to Offer Respite for Primary Sjogren's Syndrome Patients
    • LFB Group - A Key Player
  • B. Market Analytics
    • Table 43: French Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 44: French Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Outlook
    • Biotest AG - A Key Player
  • B. Market Analytics
    • Table 45: German Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 46: German Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Outlook
    • Kedrion S.p.A. - A Key Player
  • B. Market Analytics
    • Table 47: Italian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 48: Italian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • Market Analysis
    • Table 49: The UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 50: The UK Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Outlook
    • Grifols, S.A. - A Key Player
  • B. Market Analytics
    • Table 51: Spanish Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 52: Spanish Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • PRIVIGEN Debuts in Russia
    • Key Players
  • B. Market Analytics
    • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 54: Rest of Europe Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Value Analytics
    • Table 55: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 56: Asia-Pacific Historic Review for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 57: Asia-Pacific 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for Australia, China and Rest of Asia-Pacific Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 58: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 59: Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

5a. AUSTRALIA

  • A. Market Analysis
    • Overview
    • Table 60: Australian IVIg Usage by Main Indications (% of grams used annually) (includes corresponding Graph/Chart)
    • Revised Criteria for Clinical Use of IVIg in Australia
    • Australian Blood Products Market - An Overview
    • Australian Red Cross Blood Service
    • CSL Limited - A Key Player
  • B. Market Analytics
    • Table 61: Australian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 62: Australian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5b. CHINA

  • A. Market Analysis
    • Outlook
    • Overview of Chinese Blood Plasma Market
    • Table 63: Chinese Plasma Products Market by Product Type (2015): Percentage Breakdown of Value Sales for Albumin, Hyper-immune, IVIg and Others (includes corresponding Graph/Chart)
    • IVIG - Strong Opportunities Ahead
    • Domestic Players Rule IVIG Market
    • Table 64: Chinese IVIG (Intravenous Immunoglobulin) Products Market by Leading Players (2016): Percentage Breakdown of Volume Sales for China Biologic (CBPO), CNBG Shanghai Institute, Hualan Biological, Shanghai RAAS, and Others (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 65: Chinese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 66: Chinese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Plasma Fractionation in Southeast Asia - A Focus on Current and Planned Capabilities
    • Indonesia - An Overview
    • Bharat Serums And Vaccines Ltd (India) - A Key Player
  • B. Market Analytics
    • Table 67: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 68: Rest of Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Value Analytics
    • Table 69: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 70: Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 71: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 72: Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top